Back to top
more

USANA Health Sciences (USNA)

(Real Time Quote from BATS)

$29.16 USD

29.16
41,648

+0.06 (0.21%)

Updated Aug 5, 2025 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

5 Low Price-to-Book Stocks to Add to Your Portfolio in August

by Kinjel Shah

STNE, CVS, KT, KB and USNA stand out in August for low P/B ratios and strong growth forecasts, making them value stock contenders.

Zacks Equity Research

Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

USANA Health (USNA) Upgraded to Buy: Here's Why

by Zacks Equity Research

USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

USNA or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

USNA vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy Merck KGaA (MKKGY) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of +37.04% and +4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

USNA vs. STVN: Which Stock Is the Better Value Option?

by Zacks Equity Research

USNA vs. STVN: Which Stock Is the Better Value Option?

Zacks Equity Research

USANA Health (USNA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is USANA Health Sciences (USNA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

5 Low Price-to-Book Value Stocks That You Can Buy in June

by Kinjel Shah

The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.

Zacks Equity Research

USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of 4.29% and 2.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

USANA Health Sciences (USNA) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of 30.61% and 2.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Value Investors Buy USANA Health Sciences (USNA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

5 Low Price-to-Book Stocks Worthy of Value Investors' Attention

by Kinjel Shah

The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, KT, GBX, USNA and ENS are some such stocks.

Zacks Equity Research

USNA or STVN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

USNA vs. STVN: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

5 Promising Price-to-Book Value Stocks to Buy in February

by Kinjel Shah

The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, USNA, GBX, KT and ENS are some such stocks.

Zacks Equity Research

USNA vs. STVN: Which Stock Is the Better Value Option?

by Zacks Equity Research

USNA vs. STVN: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is USANA Health Sciences (USNA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks Value Investor Highlights: Alaska Air, Heidrick & Struggles, USANA Health Sciences, General Motors and Fresenius Medical Care

by Zacks Equity Research

Alaska Air, Heidrick & Struggles, USANA Health Sciences, General Motors and Fresenius Medical Care have been highlighted in this Value Investor article.

Tracey Ryniec headshot

5 Classic Value Stocks for 2025

by Tracey Ryniec

These stocks are cheap and have top Zacks Ranks of Strong Buy or Buy.